{"id":"chlorazanil","rwe":[{"pmid":"29445832","year":"2018","title":"Analytical challenges in sports drug testing.","finding":"","journal":"Analytical and bioanalytical chemistry","studyType":"Clinical Study"},{"pmid":"26226108","year":"2015","title":"Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"6840011","year":"1983","title":"[Acute interstitial nephritis caused by drugs].","finding":"","journal":"Deutsche medizinische Wochenschrift (1946)","studyType":"Clinical Study"},{"pmid":"6179386","year":"1981","title":"Investigation of the role of kidney kallikrein on bumetanide induced diuresis in rats.","finding":"","journal":"Acta pharmacologica et toxicologica","studyType":"Clinical Study"},{"pmid":"6917682","year":"1981","title":"Reduced urine kallikrein excretion and antikaliuresis by chlorazanil in rats.","finding":"","journal":"Acta pharmacologica et toxicologica","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Cobalamin deficiency","category":"indication"},{"label":"Pernicious anemia","category":"indication"},{"label":"Prevention of Vitamin B12 Deficiency","category":"indication"}],"phase":"phase_2","safety":{"contraindications":["Hypokalemia","Leber's optic atrophy"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"orpizin","offLabel":[],"synonyms":["chlorazanil hydrochloride","chlorazanil","chlorazinil","chloroazinal","diurazine","diurazyna","neurofort","orpizin","triazurol","chlorazanil HCl"],"timeline":[],"approvals":[],"brandName":"Orpizin","ecosystem":[{"indication":"Cobalamin deficiency","otherDrugs":[{"name":"cobalamin","slug":"cobalamin","company":""},{"name":"cyanocobalamin","slug":"cyanocobalamin","company":""},{"name":"hydroxocobalamin","slug":"hydroxocobalamin","company":"Watson Labs"},{"name":"thiamine","slug":"thiamine","company":"Hospira"}],"globalPrevalence":null},{"indication":"Pernicious anemia","otherDrugs":[{"name":"cobalamin","slug":"cobalamin","company":""},{"name":"cyanocobalamin","slug":"cyanocobalamin","company":""},{"name":"hydroxocobalamin","slug":"hydroxocobalamin","company":"Watson Labs"},{"name":"thiamine","slug":"thiamine","company":"Hospira"}],"globalPrevalence":null},{"indication":"Prevention of Vitamin B12 Deficiency","otherDrugs":[{"name":"cobalamin","slug":"cobalamin","company":""},{"name":"cobamamide","slug":"cobamamide","company":""},{"name":"cyanocobalamin","slug":"cyanocobalamin","company":""},{"name":"folic acid","slug":"folic-acid","company":"Lederle"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"Think of it like a shield that protects Cobalamin from being destroyed, allowing it to be used by the body to make red blood cells and maintain healthy nerve function.","oneSentence":"Orpizin works by inhibiting the breakdown of Cobalamin, allowing it to be absorbed and utilized by the body.","technicalDetail":"Orpizin is believed to exert its effects by competitively inhibiting the action of Cobalamin-binding proteins, thereby increasing the availability of Cobalamin for absorption and utilization by the body."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/591","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORAZANIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:33:14.708398","biosimilars":[],"competitors":[],"genericName":"chlorazanil","indications":{"approved":[{"name":"Cobalamin deficiency","source":"DrugCentral","snomedId":190634004,"regulator":"FDA"},{"name":"Pernicious anemia","source":"DrugCentral","snomedId":84027009,"regulator":"FDA"},{"name":"Prevention of Vitamin B12 Deficiency","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Methylmalonic acidemia","source":"DrugCentral","drugName":"CHLORAZANIL","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"48SN4K3W0E","CHEBI":"CHEBI:134911","INN_ID":"724","UMLSCUI":"C0055343","ChEMBL_ID":"CHEMBL1984344","PUBCHEM_CID":"10374","SNOMEDCT_US":"88802007","SECONDARY_CAS_RN":"2019-25-2","MESH_SUPPLEMENTAL_RECORD_UI":"C017837"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":15,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2018 Mar","pmid":"29445832","title":"Analytical challenges in sports drug testing.","journal":"Analytical and bioanalytical chemistry"},{"date":"2015 Nov 10","pmid":"26226108","title":"Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"1983 May 20","pmid":"6840011","title":"[Acute interstitial nephritis caused by drugs].","journal":"Deutsche medizinische Wochenschrift (1946)"},{"date":"1981 Nov","pmid":"6179386","title":"Investigation of the role of kidney kallikrein on bumetanide induced diuresis in rats.","journal":"Acta pharmacologica et toxicologica"},{"date":"1981 Sep","pmid":"6917682","title":"Reduced urine kallikrein excretion and antikaliuresis by chlorazanil in rats.","journal":"Acta pharmacologica et toxicologica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Orpizin, also known as Chlorazanil, is a small molecule modality developed for the treatment of Cobalamin deficiency, Pernicious anemia, and Prevention of Vitamin B12 Deficiency. However, due to the lack of available information, its target and drug class remain unknown. The commercial status of Orpizin is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine its safety profile and pharmacokinetic properties. As a result, its use should be approached with caution.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}